Hikma PHarmaceuticals Plc annual rePort 2013 Directors rePort DIRECTORS REPORT the Directors submit their report together with the audited financial statements for the 52 weeks ended 31 December 2013. this report forms the management report for the purposes of the Disclosure and transparency rules.
readers are asked to cross refer to the governance report, remuneration report and sections of other relevant reports which are included in this report to the extent necessary to meet Hikmas reporting obligations.
Donations Financial During the year the Group made charitable donations of approximately Principal activity $6.2 million 2012: $0.7 million : the principal activities of the Group are the development, manufacture amount donated amount donated type of donation in2012 $ in 2013 $ and marketing of a broad range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid and injectable final local charities serving communities in which the Group operates 304,124 5,098,321 dosage forms.
the Groups pharmaceutical operations are conducted medical donations in kind 363,740 1,105,773 through three business segments: Branded, injectables and Generic.
Political nil nil the majority of the Groups operations are in the mena region, the usand europe.
the Group does not have overseas branches within Total 667,864 6,204,094 themeaning of the companies act 2006.
Group policy prohibits the payment of political donations.
the Groups net sales, gross profit and operating profit are shown by business segment in note 4 to the consolidated financial research and development statements.
Hikma has not capitalised any interest payments.
the Groups investment in research and development r&D during 2013 represented 2.9% of Group revenue 2012: 3.1%.
additionally, results the Group invested extensively in the purchase of certain products.
the Groups profit for the year in 2013 was $216 million 2012: Further details on the Groups r&D activities can be found on page 35.
related party transactions Dividend Details of related party transactions are included in note 38 of the the Board is recommending a final dividend of 13 cents per share financial statements on page 165. approximately 7.8 pence 2012: 10 cents and a special dividend of 4cents per share approximately 2.4 pence.
the special dividend Going concern reflects the exceptional performance of the Generics business over the Directors believe that the Group is well diversified due to its the period.
the proposed dividends will be paid on 22 may 2014 to geographic spread, product diversity and large customer and shareholders on the register on 25 april 2014, subject to approval at supplier base.
the Group operates in the relatively defensive generic the annual General meeting on 15 may 2014. pharmaceuticals industry which the Directors expect to be less affected an interim dividend of 7.0 cents per share plus a special dividend compared to other industries.
of 3.0 cents was paid on 7 october 2013 together approximately the Group has decreased its year end net debt position to 6.06pence per ordinary share 2012: 7 cents.
the total dividend for $267million 2012: $405 million.
operating cash flow in 2013 the year 2013 is 27 cents per share 2012: 16.0 cents, of which 7 cents was $337 million 2012: $184 million.
the Group has $376 million is aspecial dividend.
2012:$313 million of undrawn banking facilities.
these facilities are well diversified across the operating subsidiaries of the Group and are creditor payment policy with a number of financial institutions.
the Groups forecasts, taking Hikmas policy, which is also applied by the Group and will continue in into account reasonable possible changes in trading performance, respect of the 2014 financial year, is to settle terms of payment with all facility renewal sensitivities and maturities of long-term debt, show suppliers when agreeing the terms of each transaction and to ensure that the Group should be able to operate well within the levels of that suppliers are made aware of and abide by the terms of payment.
itsfacilities and their related covenants.
trade creditors of Hikma at 31 December 2013 were equivalent to 73days purchases 2012: 66 days, based on the average daily amount invoiced by suppliers during the year.
116 corPorate Governance after making enquiries, the Directors believe that the Group is shareholders are referred to the effectiveness report on pages 65 to 66, adequately placed to manage its business and financing risks which provides further detail on the balance of skills and experience successfully despite the current uncertain economic and political onthe Board.
the Directors have formed a judgement that there is indemnities reasonable expectation that the Group has adequate resources the Directors benefit from qualifying third party indemnities made by to continue in operational existence for the foreseeable future.
Hikma which were in force during the year and as at the date of this the Directors therefore continue to adopt the going concern basis report.
these indemnities are uncapped in amount in relation to losses inpreparing the financial statements.
and liabilities which Directors may incur to third parties in the course significant contracts ofthe performance of their duties.
Due to the nature of the Groups business, members of the Group are party to agreements that could alter or be terminated upon a eQuitY change of control of the Group following a takeover.
However, none capital structure of these agreements is individually deemed to be significant in terms Details of the issued share capital, together with movements in the of its potential impact on the business of the Group taken as a whole.
issued share capital during the year can be found in note 31 to the the Directors are not aware of any agreements between Hikma and its financial statements.
Hikma has one class of ordinary shares which Directors or employees that provide for compensation for loss of office carries no right to fixed income.
each share carries the right to one or employment that occurs because of a takeover bid.
voteat general meetings of Hikma.
there are no persons, with whom Hikma has contractual or as at 31 December 2013: other arrangements, who are deemed to be essential to the business issued during of Hikma.
type nominal value in issue the year auditors ordinary 10 pence 198,044,328 1,007,821 each person who was a Director of Hikma at the date when this report During 2013, Hikma issued ordinary shares solely pursuant to the was approved confirms that: exercise of options under the Hikma Pharmaceuticals Plc 2004 stock so far as the Director is aware, there is no relevant audit information option Plan, 2005 long term incentive Plan and 2009 management ofwhich Hikmas auditors are unaware incentive Plan.
the Director has taken all the steps that he ought to have taken as there are no specific restrictions on the size of a holding or on the aDirector to make himself aware of any relevant audit information transfer of shares, which are both governed by the general provisions andto establish that Hikmas auditors are aware of that information of Hikmas articles of association the articles and prevailing legislation.
the Directors are not aware of any agreements between this confirmation is given and should be interpreted in accordance holders of Hikmas shares that may have resulted in restrictions on the with the provisions of section 418 of the companies act 2006. transfer of securities or on voting rights.
no person has any special Deloitte llP has expressed its willingness to continue in office rights with regard to the control of Hikmas share capital and all issued asauditors and a resolution to reappoint them will be proposed at the shares are fully paid.
Hikma has not placed any shares into treasury forthcoming annual General meeting.
during the period under review.
Directors share buy back at the annual General meeting on 16 may 2013, shareholders gave the names of the Directors as at the date of this report, together the Directors authority to purchase shares from the market up to with details of their roles, backgrounds and abilities, are set out in the an amount equal to 10% of Hikmas issued share capital at that Directors biographies on pages 54 to 57.
Details of the independence time.
this authority expires at the earlier of 30 June 2014 or the of non-executive Directors are set out in the report on corporate 2014 annual General meeting, which is scheduled for 15 may 2014. governance on page 65. all the executive and non-executive Directors the Directors are proposing to renew this authority at the 2014 annual served Hikma throughout the year.
the appointment of mr Pat Butler General meeting.
as a Director effective 1 april 2014 was approved on 11 march 2014.
During the year, Hikma acquired 210,000 of its own ordinary it is the Boards policy that all Directors should retire and seek shares of 0.10 each at an average price of 10.13 per share as detailed re-election on an annual basis.
accordingly, samih Darwazah, in the table below.
the shares purchased are held either in treasury saidDarwazah, mazen Darwazah, sir David rowe-Ham, ali al-Husry, orby the employee Benefit trust.
Breffni Byrne, michael ashton, ronald Goode, robert Pickering and Pat Butler will retire at the annual General meeting.
all Directors will seek election or re-election at the annual General meeting with the exception of samih Darwazah and sir David rowe-Ham.
117 Hikma PHarmaceuticals Plc annual rePort 2013 Directors rePort Continued number of ordinary Highest price paid lowest price paid name of shareholder number of shares Percentage held Date shares purchased per share per share Darhold limited 57,183,028 28.9% 30 august 2013 35,000 10.15 10.14 capita Group international 5,952,422 3.0% 28 august 2013 175,000 10.14 10.07 Fidelity international 9,873,932 5.0% DuPont capital management 19,232,981 9.7% share issuance messrs samih Darwazah, said Darwazah, mazen Darwazah and ali al-Husry, each being a Director and at the annual General meeting on 16 may 2013, the Directors were shareholder of Hikma, are shareholders and Directors of Darhold limited.
see page 109 for details of their holdings in Darhold authorised to issue relevant securities up to an aggregate nominal amount of 6,582,812, and to be empowered to allot equity securities Pre-emptive issue of shares for cash on a non pre-emptive basis up to an aggregate nominal During the year under review, and in the period since 1 november amount of 987,422, at any time up to the earlier of the date of the 2005, the date of Hikmas iPo, Hikma did not issue any ordinary 2014 annual General meeting or 30 June 2014. the Directors propose shares pursuant to an authority given by shareholders at an to renew these authorities at the 2014 annual General meeting for annualGeneral meeting to issue ordinary shares for cash on a non a further year.
in the year ahead, other than in respect of Hikmas pre-emptive basis, other than in respect of the placing undertaken obligations to satisfy rights granted to employees under its various on17 January 2008. share-based incentive arrangements, the Directors have no present takeover panel rule 9 intention of issuing any share capital of Hikma.
ltiP granted miP granted Details of the employee share schemes are set out in note 18 may 2013 18 may 2013 36 to the financial statements.
shares are also held by the Hikma said Darwazah 103,000 Pharmaceuticals employee Benefit trust eBt and are detailed mazen Darwazah 52,000 innote 33 to the financial statements.
the eBt has waived its right may Darwazah 481 tovote on the shares it holds and also to its entitlement to a dividend.
no other shareholder has waived the right to a dividend.
Hana ramadan 2,304 tareq Darwazeh 2,154 annual General meeting Zeena murad 1,679 the annual General meeting of Hikma will be held at the Westbury, Bond street, mayfair, london W1s 2YF on thursday, 15 may 2014, at the annual General meeting held on 16 may 2013, a vote of the starting at 11.00 a. m. the notice convening the meeting is given in independent shareholders of Hikma approved the award of up to a separate document accompanying this document, and includes an aggregate of 155,000 ordinary shares pursuant to Hikmas 2005 a commentary on the business of the aGm, and notes to help long term incentive Plan to said Darwazah and mazen Darwazah shareholders exercise their rights at the meeting.
the ltiP Holders and 25,000 ordinary shares pursuant to the the powers of the Directors are determined by the articles, management incentive Plan to Hana ramadan, may Darwazah, Zeena thecode and other relevant uk legislation.
the Directors powers are murad, tareq Darwazah and Walid Darwazeh the miP Holders.
detailed in the corporate governance report on page 69. the articles Because of the relationship of the ltiP Holders and the miP Holders give the Directors the power to appoint and remove Directors and with Darhold limited, who at the time of the annual General meeting theyalso provide for re-election at three-yearly intervals.
the power held 57,183,028 ordinary shares at 8 april 2013 representing 28.96% toissue and allot shares contained in the articles is subject to of the issued share capital of Hikma, andas at 11 march 2014 being shareholder approval at each annual General meeting.
the articles, the latest practicable date prior to thepublication of this document, which are available on the website, may only be amended by special holding 57,183,028 ordinary shares, representing 28.874% of the resolution ofthe shareholders.
issued share capital of Hikma, each of the ltiP Holders and the miP Holders together with certain other identified individuals at that date Directors interests was treated as acting in concert with Darhold limited for the purposes Details of Directors share-based incentives and interests in the of the takeover code the concert Party.
as at 8 april2013, the ordinary shares of Hikma are provided in the Directors remuneration concert Party held, in aggregate, interests in 63,850,460 ordinary report on page 109. shares in the capital of Hikma then representing 32.33% of the then substantial shareholdings issued share capital of Hikma.
as at 11 march 2014 being the latest as at the date of this document, Hikma had been notified pursuant practicable date prior to the publication of this document, the concert to sections 89a to 89l of the Financial services and markets act 2000 Party held, in aggregate, interests in 62,745,392 ordinary shares in the and rule 5 of the Disclosure and transparency rules of the ukla of capital of Hikma representing 31.68% of the then issued share capital the following interests in the voting rights attaching to the share capital of Hikma.
of Hikma: 118 corPorate Governance Holding if all existing soP, Holding if maximum award Holding, 8 april 2013 Holding, 11 march 2014 miP, ltiP are exercised granted in 2014 exercised no.
of Percentage of ordinary issued share ordinary issued share ordinary issued share ordinary issued share shares capital shares capital shares capital shares capital Darhold limited 57,183,028 28.96% 57,183,028 28.87% concert Party 63,850,460 32.33% 62,745,392 31.68% 63,263,598 31.56% 63,417,098 31.64% on full exercise of the options under the Hikma Pharmaceuticals 2004 the Directors are responsible for keeping adequate accounting records stock option Plan the 2004 Plan and full vesting of the ltiPs and that are sufficient to show and explain the companys transactions the miPs, the concert Party would potentially have, in aggregate, and disclose with reasonable accuracy at any time the financial interests in 63,417,098 shares in the capital of Hikma representing position of the company and enable them to ensure that the financial 31.64% of the enlarged issued share capital of Hikma, on the basis statements comply with the companies act 2006. they are also that no ordinary shares were issued other than pursuant to the responsible for safeguarding the assets of the company and hence for exercise of such options or vesting of ltiPs miPs.
taking reasonable steps for the prevention and detection of fraud and During the period from the annual General meeting in 2013 to other irregularities.
11 march 2014, the ltiP miP Holders together with other members the Directors are responsible for the maintenance and integrity of the concert Party who hold options over ordinary shares pursuant of the corporate and financial information included on the companys to Hikmas 2005 long term incentive Plan and 2009 management website.
legislation in the united kingdom governing the preparation incentive Plan each an option Holder exercised, in aggregate, and dissemination of financial statements may differ from legislation options over 136,517 ordinary shares in the capital of Hikma.
We confirm to the best of our knowledge: Directors resPonsiBilitY statement the financial statements, prepared in accordance with international Financial reporting standards, give a true and fair view of the assets, the directors are responsible for preparing the annual report and liabilities, financial position and profit or loss of the company and the the financial statements in accordance with applicable law and undertakings included in the consolidation taken as a whole regulations.
company law requires the Directors to prepare financial the strategic report includes a fair review of the development and statements for each financial year.
under that law the Directors are performance of the business and the position of the company and the required to prepare the Group financial statements in accordance with undertakings included in the consolidation taken as a whole, together international Financial reporting standards iFrss as adopted by with a description of the principal risks and uncertainties that they face the european union and article 4 of the ias regulation and have also the annual report and Financial statements, taken as a whole, are fair, chosen to prepare the Parent company financial statements under balanced and understandable and provide the information necessary for iFrss as adopted by the eu.
under company law the Directors must shareholders to assess the companys performance, business model and not approve the accounts unless they are satisfied that they give a strategy true and fair view of the state of affairs of the company and ofthe profit or loss of the company for that period.
in preparing these By order of the Board financial statements, international accounting standard 1 requires that Directors: Said Darwazah Mazen Darwazah Properly select and apply accounting policies Chief Executive Officer Executive Vice Chairman Present information, including accounting policies, in a manner that 11 March 2014 provides relevant, reliable, comparable and understandable information Provide additional disclosures when compliance with the specific requirements in iFrss are insufficient to enable users to understand theimpact of particular transactions, other events and conditions ontheentitys financial position and financial performance make an assessment of the companys ability to continue asagoingconcern 119 Hikma PHarmaceuticals Plc annual rePort 2013 H el Pi ng to improve l i v e s 120
